Drug Detail:Ceritinib (Ceritinib [ se-ri-ti-nib ])
Drug Class: Multikinase inhibitors
Ceritinib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of ceritinib during breastfeeding. Because ceritinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ceritinib therapy and for 2 weeks after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Ceritinib
CAS Registry Number
1032900-25-6
Drug Class
-
Breast Feeding
-
Lactation
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Protein Kinase Inhibitors
-
Signal Transduction Inhibitors
-
Tyrosine Kinase Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification